Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course

Lung Cancer

Volumn 69, Issue 3, 2010, Pages 361-364

  Murakami, Shuji ^a   Yokose, Tomoyuki ^a   Saito, Haruhiro ^a   Sakuma, Yuji ^a   Matsukuma, Shoichi ^a   Hasegawa, Chikako ^a   Kondo, Tetsuro ^a   Oshita, Fumihiro ^a   Ito, Hiroyuki ^a   Tsuboi, Masahiro ^a   Nakayama, Haruhiko ^a   Kameda, Youichi ^a   Noda, Kazumasa ^a   Yamada, Kouzo ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Adenocarcinoma; EML4 ALK; Recurrence; Signet ring cell

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN; PROTEIN EML4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GENETICS; CASE REPORT; DISEASE COURSE; EML4 GENE; FEMALE; FUSION GENE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; INCIDENCE; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER;

EID: 77955092588     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.05.019     Document Type: Article

References (12)

1. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
3. Matsukuma S., Yoshihara M., Kasai F., Kato A., Yoshida A., Akaike M., et al. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn 2006, 8:504-512.
4. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.
5. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
6. Inamura K., Takeuchi K., Togashi Y., Hatano S., Ninomiya H., Motoi N., et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009, 22:508-515.
7. Martini N., Melamed M.R. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975, 70:606-612.
8. Girard N., Deshpande C., Lau C., Finley D., Rusch V., Pao W., et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009, 33:1752-1764.
9. Rubins J., Unger M., Colice G.L. Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 2007, 132:355S-367S.
10. Girard N., Deshpande C., Azzoli C.G., Rusch V.W., Travis W.D., Ladanyi M., et al. Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines. Chest 2010, 137(January (1)):46-52. [Epub 2009 April 17].
11. Boland J.M., Erdogan S., Vasmatzis G., Yang P., Tillmans L.S., Johnson M.R., et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009, 40:1152-1158.
12. Takahashi T., Sonobe M., Kobayashi M., Yoshizawa A., Menju T., Nakayama E., et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2009.